Dr. KSS MD PhD

Author Bio

Dr. KSS MD PhD
I am an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, I have been investing in biotech companies. I earned my degrees at a top 10 US institution, where I was an NIH scholar and graduated with top honors. I have extensive post-doctoral research experience and am board certified in internal medicine and gastroenterology. I am a member of Phi Beta Kappa and Alpha Omega Alpha (academic honor societies, the latter in medicine) and am a Fellow of the American College of Physicians, the American equivalent of being FRCP in certain Anglophone countries. My hobbies are traveling (I have been to 100 countries), chamber music, literature, film and Asian pottery. My goal as a Stock Gumshoe contributor is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities. Dr. KSS is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

Cisco, Chang & Charlie Part 3

Sometimes literary gimmicks backfire. In May 2015, we premiered “Cisco, Chang & Charlie” (sans Oxford comma) as a James Joycean brooding on the letter C, third letter of the alphabet, in three iterations. At the time, three stocks whose names begin with C were vying for attention and prompting questions from readers. The original plan […]

Oncotutorial

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]

Long Idea of the Year

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his old articles and his most recent comments on his Stock Gumshoe page.] “Keep it quiet. (Go slow.) […]

Quickster: Update on Corbus

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. To see all of his column and his latest comments, go to his Stock Gumshoe page.] [Author’s note: This commentary has been […]

The 12 Biotechs of Christmas: Six

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Let’s turn our attention today, in a mild […]

The 12 Biotechs of Christmas: Five

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Our fifth stock on this Christmas outing is […]

The 12 Biotechs of Christmas: Four

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] It’s a warm Sunday afternoon a few months […]

The Twelve Biotechs of Christmas: Two

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] After the New Year, we plan to look […]

Such A Pleasant Stay

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Thanks to you I’m much obliged Such a […]

Sea of Tranquility

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “I live in the light of the bright summer […]

Recent Author Comments

On Cisco, Chang & Charlie Part 3
OncoNova (ONTX) is a small Pennsylvanian biotech advancing oral rigosertib through clinical trials. That drug inhibits PI3 kinase and a serine/threonine kinase, and is regarded as having the ability to control rate of progression of MDS (now in phase 3). I[...]
On Cisco, Chang & Charlie Part 3
Why has Corbus refused to evaluate anabasum in human NASH? That's the most widespread chronic parenchymal inflammatory condition the overnourished human race faces. And what every other pharma is chasing. Why not Corbus? Answer: because probably they di[...]
On Cisco, Chang & Charlie Part 3
If you're brain damaged beyond recognition you certainly don't live to be 95.[...]
On Cisco, Chang & Charlie Part 3
I can't agree. $ISCO has been trying to postpone its corporate demise for 20 years, yet lacks the mettle to bite down and actually accomplish anything. "Move forward" is a meaningless phrase and could mean the first patient is still 5 years away.....which [...]
On Cisco, Chang & Charlie Part 3
Agree. For a pugilist to live to 95, that's unheard of! What was different about him neurologically??? Oh, I know ALL about Belleville: my ex-wife is from there. I saw Raging Bull soon after its theatrical release, sometime in the early 1980s. I predicted[...]
On Cisco, Chang & Charlie Part 3
Memo to self: Remember to be nice to Traydon if he dies to offset the bad karma he's incurred from being negative about something pertaining to La Motta on the day of La Motta's death. La Motta was a hero, epic, and very human, and "Raging Bull" is a pe[...]
On Cisco, Chang & Charlie Part 3
Liposarcomas are rare, poorly characterized, often barely playing by cancer rules. Many can be excised without need for chemo. Others shrink massively in response to propranolol, an old nonselective beta-blocker. It's just the sort of disease no one will e[...]
On Cisco, Chang & Charlie Part 3
Hi Jabber: Here's what I think is a pretty careful, lucid appraisal of $KPTI. I once had a position, vacated that, and have no intention of re-entering. And here is why. First of all, for me to put a biotech stock on a list that I think readers should con[...]
On Cisco, Chang & Charlie Part 3
$RGLS up 6 percent pre-market. Chartologists have been calling for a breakout here for 2-3 weeks based on technical formations. And this would be consistent with insider buying. I've reviewed the science behind their Alport program, and think it's likely t[...]
On Cisco, Chang & Charlie Part 3
Agree with Paul. After it opens in a few minutes, we will have a better sense as to how things will trade today in $CAPR shares. It's simplistic modeling, and we don't yet know a diluted share count, but reckoning the value of this stock here seems to me t[...]
On Cisco, Chang & Charlie Part 3
Thanks zz.[...]
On Cisco, Chang & Charlie Part 3
yes....planning to attend,[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
The entire float has now officially traded for the day.[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
OK, Jammin.....which island are you buying THIS time???[...]
On Rodman and Renshaw Presentation Notes, Day Two
I agree with you. She is the strongest part of the $PSDV long thesis.[...]
On Cisco, Chang & Charlie Part 3
That article is a Stat-Plus article behind a paywall, and sadly I'll not pay to read their raker of muck's musings. Portola did NOT massage phase 3 failure, and Feuerstein, neither doctor, scientist nor statistician, isn't qualified to make such a call. Lo[...]
On Cisco, Chang & Charlie Part 3
Well, what's YOUR view of $TTOO? What prompts you to ask? Do you have a position in shares?[...]
On Cisco, Chang & Charlie Part 3
Sorry....I missed that comment. But had I seen it, I would have said, I think, that I was ready to go long finally after two years of $CAPR being in a wasteland. Rumors have been swirling that they've really made these DMD patients feel better...and if the[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
Honor roll post.[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
Thanks for letting us know what you're doing....I like when readers do that. I think you've made excellent decisions.[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.